Recombinant antibody production services

We produce a wide range of recombinant antibody formats: IgG, IgA, IgE, IgM, scFv, Fab, VHH, bispecifics, and Fc-fusion proteins, across different isotypes.

Absolutely. Our services are designed to be 100% customizable, from the expression system and vector choice to purification strategies and integrated QC testing.

These three production modes all rely on recombinant technologies but serve distinct needs at different stages of antibody development:

• High-throughput production:

Based on transient expression (genes are not integrated into the host genome), this approach allows the simultaneous generation of dozens to hundreds—even thousands—of antibodies in small amounts (from µg to a few mg, depending on conditions). Fast and cost-effective, it is ideal for early-stage screening projects where the goal is to rapidly eliminate large numbers of candidates. Characterization is typically limited to keep costs and timelines manageable.

• Transient production:

Like high-throughput production, transient production relies on temporary gene expression, but at larger scales (from 30 mL up to several liters). It is generally used to produce a limited number of candidates (from one to a few dozen) in quantities ranging from milligrams to grams. This makes it a perfect choice for intermediate stages such as antibody optimization or lead candidate selection, where detailed characterization is required to support critical decision-making.

• Stable cell line development:

In this method, the gene is permanently integrated into the host cell genome, enabling long-term, high-yield production. Stable cell lines are typically used for large-scale production, from preclinical studies to clinical trials and industrial biomanufacturing. Although it is a longer, more complex, and generally more expensive process, it includes comprehensive characterization due to its strategic role in the drug development value chain.

It depends on factors such as the number of antibodies, the required quantity, and your budget. Our experts are here to guide you to the most efficient strategy for your specific goals.

Yes. Many projects begin with transient expression and transition to stable cell line development once advanced.

We offer a wide range of analytical and functional characterizations, providing a full identity card of your antibody. This can include the assessment of several properties such as:

• Binding acitivity
• Identity
• Purity
• Stability
• Monodispersity
• Glycosylation
• Endotoxin/sterility
• Immunogenicity
• Structure
• Degradation products

Yes. ProteoGenix is ISO 9001:2015 and ISO 14001:2015 certified. This ensures you are working with a partner committed to quality, client satisfaction, and sustainability.

Absolutely. All our production services are 100% royalty-free. You pay only for the service, and you remain the full owner of your deliverables. No hidden fees, no royalties, no surprises.